Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced that the Hong Kong Department of Health has granted the Certificate for Clinical Trial / Medicinal Test for lead investigational therapy, PLT012 in patients with advanced solid tumors.
The study will be conducted at the Phase I Clinical Trial Centre, under the Department of Clinical Oncology of The Chinese University of Hong Kong. The regulatory approval authorizes Pilatus to initiate a clinical trial evaluating PLT012 in Hong Kong, and represents an important milestone in advancing the Company’s global clinical development program to advance the novel therapy for patients with advanced solid tumors, including liver cancer and gastrointestinal cancers.
Pilatus also announced the establishment of its Hong Kong subsidiary, expanding its presence in one of Asia’s leading biotechnology and clinical-research hubs. The company has worked closely with Invest Hong Kong (InvestHK) to establish its regional operations and plans to leverage Hong Kong’s growing life sciences ecosystem to support clinical development, academic and strategic collaborations, and engagement with regional investment opportunities.
“We are pleased to receive CTA approval, which enables the PLT012 clinical study to commence in Hong Kong. We look forward to working with the study team to evaluate the safety and clinical potential of this investigational therapy in patients with advanced solid tumors,” said Dr. Stephen Chan, principal study investigator and clinical professor at the Department of Clinical Oncology of The Chinese University of Hong Kong.
